Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Inotiv prepackaged chapter 11 filing and restructuring support agreement
We are advising an ad hoc group of first-lien lenders in connection with Inotiv’s chapter 11 proceedings
Inventiva $120 million underwritten offering
We advised the underwriters on the offering
Sumitomo Pharma ¥102.1 billion stock offering
We advised the joint lead managers and joint bookrunners on the offering
Roche acquisition of SAGA Diagnostics
We advised Roche on the transaction
CARsgen HK$470 million placement of shares and top-up subscription
We advised CARsgen on the placement and top-up subscription
Ingenovis Health comprehensive restructuring transactions
We advised Ingenovis Health in connection with the restructuring
Editas Medicine $125 million follow-on offering
We advised the joint book-running managers on the offering
Merck $6 billion notes offering
We advised the underwriters on the offering
Immix Biopharma $150 million stock offering
We advised the lead bookrunner and the underwriters on the offering
Oruka Therapeutics collaboration with Halozyme
We advised Oruka Therapeutics on the transaction